Targeting two-pore domain K+ channels TREK-1 and TASK-3 for the treatment of depression: A new therapeutic concept

British Journal of Pharmacology

Volumn 172, Issue 3, 2015, Pages 771-784

  Borsotto, M ^a   Veyssiere, J ^a   Moha Ou Maati, H ^b   Devader, C ^a   Mazella, J ^a   Heurteaux, Catherine ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; SEROTONIN; SORTILIN; SPADIN; TANDEM PORE DOMAIN POTASSIUM CHANNEL; TANDEM PORE DOMAIN WEAK INWARD RECTIFYING POTASSIUM RELATED ACID SENSITIVE POTASSIUM CHANNEL 3; TANDEM PORE DOMAIN WEAK INWARD RECTIFYING POTASSIUM RELATED POTASSIUM CHANNEL 1; UNCLASSIFIED DRUG; KCNK9 PROTEIN, HUMAN; PEPTIDE; POTASSIUM CHANNEL PROTEIN TREK-1; SPADIN PEPTIDE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; DEPRESSION; DISEASE ASSOCIATION; GENE; GENETIC ASSOCIATION; HUMAN; KCNK9 GENE; KNOCKOUT MOUSE; MEMORY DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; WHOLE CELL PATCH CLAMP; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN;

EID: 84920829438     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12953     Document Type: Article

References (103)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
5. Aller MI, Veale EL, Linden AM, Sandu C, Schwaninger M, Evans LJ et al. (2005). Modifying the subunit composition of TASK channels alters the modulation of a leak conductance in cerebellar granule neurons. J Neurosci 25: 11455-11467.
6. Alloui A, Zimmermann K, Mamet J, Duprat F, Noel J, Chemin J et al. (2006). TREK-1, a K+ channel involved in polymodal pain perception. EMBO J 25: 2368-2376.
7. Barel O, Shalev SA, Ofir R, Cohen A, Zlotogora J, Shorer Z et al. (2008). Maternally inherited Birk Barel mental retardation dysmorphism syndrome caused by a mutation in the genomically imprinted potassium channel KCNK9. Am J Hum Genet 83: 193-199.
8. Bayliss DA, Sirois JE, Talley EM (2003). The TASK family: two-pore domain background K+ channels. Mol Interv 3: 205-219.
9. Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC et al. (2010). Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 44: 1205-1213.
10. Bennett AJ, Lesch KP, Heils A, Long JC, Lorenz JG, Shoaf SE et al. (2002). Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry 7: 118-122.
11. Berg AP, Talley EM, Manger JP, Bayliss DA (2004). Motoneurons express heteromeric TWIK-related acid-sensitive K+ (TASK) channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits. J Neurosci 24: 6693-6702.
12. Bittner S, Budde T, Wiendl H, Meuth SG (2010). From the background to the spotlight: TASK channels in pathological conditions. Brain Pathol 20: 999-1009.
13. Bittner S, Ruck T, Schuhmann MK, Herrmann AM, Moha ou Maati H, Bobak N et al. (2013). Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. Nat Med 19: 1161-1165.
14. Blier P (2001). Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 62 (Suppl. 4): 7-11, discussion 37-40.
15. Blondeau N, Petrault O, Manta S, Giordanengo V, Gounon P, Bordet R et al. (2007). Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res 101: 176-184.
16. Bogdan R, Fitzgibbon H, Woolverton WL, Bethea CL, Iyo AH, Stockmeier CA et al. (2011). 5-HTTLPR genotype and gender, but not chronic fluoxetine administration, are associated with cortical TREK1 protein expression in rhesus macaques. Neurosci Lett 503: 83-86.
17. Brown ES, Rush AJ, McEwen BS (1999). Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 21: 474-484.
18. Buckler KJ, Williams BA, Honore E (2000). An oxygen-, acid- and anaesthetic-sensitive TASK-like background potassium channel in rat arterial chemoreceptor cells. J Physiol 525 (Pt 1): 135-142.
19. Burdakov D, Jensen LT, Alexopoulos H, Williams RH, Fearon IM, O'Kelly I et al. (2006). Tandem-pore K+ channels mediate inhibition of orexin neurons by glucose. Neuron 50: 711-722.
20. Caldarone BJ, George TP, Zachariou V, Picciotto MR (2000). Gender differences in learned helplessness behavior are influenced by genetic background. Pharmacol Biochem Behav 66: 811-817.
21. Carlo AS, Nykjaer A, Willnow TE (2014). Sorting receptor sortilin - a culprit in cardiovascular and neurological diseases. J Mol Med (Berl) 92: 905-911.
22. Chemin J, Girard C, Duprat F, Lesage F, Romey G, Lazdunski M (2003). Mechanisms underlying excitatory effects of group I metabotropic glutamate receptors via inhibition of 2P domain K+ channels. EMBO J 22: 5403-5411.
23. Coburn CA, Luo Y, Cui M, Wang J, Soll R, Dong J et al. (2012). Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3). ChemMedChem 7: 123-133.
24. Coutinho MF, Prata MJ, Alves S (2012). Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. Mol Genet Metab 105: 542-550.
25. Cryan JF, Mombereau C (2004). In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9: 326-357.
26. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
27. Deng PY, Lei S (2008). Serotonin increases GABA release in rat entorhinal cortex by inhibiting interneuron TASK-3 K+ channels. Mol Cell Neurosci 39: 273-284.
28. Dillon DG, Bogdan R, Fagerness J, Holmes AJ, Perlis RH, Pizzagalli DA (2010). Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans. Hum Brain Mapp 31: 210-221.
29. Duman RS, Malberg J, Thome J (1999). Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 46: 1181-1191.
30. Duprat F, Lesage F, Fink M, Reyes R, Heurteaux C, Lazdunski M (1997). TASK, a human background K+ channel to sense external pH variations near physiological pH. EMBO J 16: 5464-5471.
31. + channels TREK-1 and TRAAK. Mol Pharmacol 57: 906-912.
32. Enyedi P, Czirjak G (2010). Molecular background of leak K+ currents: two-pore domain potassium channels. Physiol Rev 90: 559-605.
33. Evans SF, Irmady K, Ostrow K, Kim T, Nykjaer A, Saftig P et al. (2011). Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation. J Biol Chem 286: 29556-29567.
34. Garry A, Fromy B, Blondeau N, Henrion D, Brau F, Gounon P et al. (2007). Altered acetylcholine, bradykinin and cutaneous pressure-induced vasodilation in mice lacking the TREK1 potassium channel: the endothelial link. EMBO Rep 8: 354-359.
35. Girard C, Tinel N, Terrenoire C, Romey G, Lazdunski M, Borsotto M (2002). p11, an annexin II subunit, an auxiliary protein associated with the background K+ channel, TASK-1. EMBO J 21: 4439-4448.
36. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102: 18620-18625.
37. Gordon JA, Hen R (2006). TREKing toward new antidepressants. Nat Neurosci 9: 1081-1083.
38. Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW et al. (2011). TASK-3 as a potential antidepressant target. Brain Res 1416: 69-79.
39. Gould E (1999). Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 21: 46S-51S.
40. Haddjeri N, Blier P, de Montigny C (1998). Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18: 10150-10156.
41. Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M et al. (2004). TREK-1, a K(+) channel involved in neuroprotection and general anesthesia. EMBO J 23: 2684-2695.
42. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng X et al. (2006). Deletion of TREK-1, a background potassium channel, results in a depression-resistant phenotype. Nat Neurosci 9: 1134-1141.
43. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G et al. (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115: 3104-3116.
44. Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A et al. (2009). Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 52: 932-940.
45. Kameyama T, Nagasaka M, Yamada K (1985). Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology 24: 285-290.
46. Kananura C, Sander T, Rajan S, Preisig-Muller R, Grzeschik KH, Daut J et al. (2002). Tandem pore domain K(+)-channel TASK-3 (KCNK9) and idiopathic absence epilepsies. Am J Med Genet 114: 227-229.
47. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A (2005). Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 144: 821-829.
48. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602.
49. Kim D (2005). Physiology and pharmacology of two-pore domain potassium channels. Curr Pharm Des 11: 2717-2736.
50. Kim E, Hwang EM, Yarishkin O, Yoo JC, Kim D, Park N et al. (2010). Enhancement of TREK1 channel surface expression by protein-protein interaction with beta-COP. Biochem Biophys Res Commun 395: 244-250.
51. Lauritzen I, Zanzouri M, Honore E, Duprat F, Ehrengruber MU, Lazdunski M et al. (2003). K+-dependent cerebellar granule neuron apoptosis. Role of task leak K+ channels. J Biol Chem 278: 32068-32076.
52. Lesage F (2003). Pharmacology of neuronal background potassium channels. Neuropharmacology 44: 1-7.
53. Lesage F, Lazdunski M (2000). Molecular and functional properties of two pore domain potassium channels. Am J Physiol 279: 793-801.
54. Lesage F, Guillemare E, Fink M, Duprat F, Lazdunski M, Romey G et al. (1996). TWIK-1, a ubiquitous human weakly inward rectifying K+ channel with a novel structure. EMBO J 15: 1004-1011.
55. Linden AM, Sandu C, Aller MI, Vekovischeva OY, Rosenberg PH, Wisden W et al. (2007). TASK-3 knockout mice exhibit exaggerated nocturnal activity, impairments in cognitive functions, and reduced sensitivity to inhalation anesthetics. J Pharmacol Exp Ther 323: 924-934.
56. Liou YJ, Chen TJ, Tsai SJ, Yu YW, Cheng CY, Hong CJ (2009). Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment. Pharmacogenet Genomics 19: 735-741.
57. Maingret F, Patel AJ, Lazdunski M, Honore E (2001). The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J 20: 47-54.
58. Massa F, Devader C, Beraud-Dufour S, Brau F, Coppola T, Mazella J (2013). Focal adhesion kinase dependent activation of the PI3 kinase pathway by the functional soluble form of neurotensin receptor-3 in HT29 cells. Int J Biochem Cell Biol 45: 952-959.
59. Massa F, Devader C, Lacas-Gervais S, Béraud-Dufour S, Coppola T, Mazella J (2014). Impairement of HT29 cancer cells cohesion by the soluble form of neurotensin receptor-3. Genes Cancer 5: 240-249.
60. Mazella J, Zsurger N, Navarro V, Chabry J, Kaghad M, Caput D et al. (1998). The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem 273: 26273-26276.
61. Mazella J, Petrault O, Lucas G, Deval E, Beraud-Dufour S, Gandin C et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol 8: e1000355.
62. Mazella J, Beraud-Dufour S, Devader C, Massa F, Coppola T (2012). Neurotensin and its receptors in the control of glucose homeostasis. Front Endocrinol (Lausanne) 3: 143.
63. Meuth SG, Budde T, Kanyshkova T, Broicher T, Munsch T, Pape HC (2003). Contribution of TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 channels to the control of activity modes in thalamocortical neurons. J Neurosci 23: 6460-6469.
64. Meuth SG, Kleinschnitz C, Broicher T, Austinat M, Braeuninger S, Bittner S et al. (2009). The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. Neurobiol Dis 33: 1-11.
65. Moha ou Maati H, Veyssiere J, Labbal F, Coppola T, Gandin C, Widmann C et al. (2012). Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology 62: 278-288.
66. Muhammad S, Aller MI, Maser-Gluth C, Schwaninger M, Wisden W (2010). Expression of the kcnk3 potassium channel gene lessens the injury from cerebral ischemia, most likely by a general influence on blood pressure. Neuroscience 167: 758-764.
67. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, Gliemann J et al. (1999). Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J 18: 595-604.
68. Navarro V, Vincent JP, Mazella J (2002). Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line. Biochem Biophys Res Commun 298: 760-764.
69. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25.
70. Nibuya M, Nestler EJ, Duman RS (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16: 2365-2372.
71. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM (1999). Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J Biol Chem 274: 8832-8836.
72. Noel J, Zimmermann K, Busserolles J, Deval E, Alloui A, Diochot S et al. (2009). The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. EMBO J 28: 1308-1318.
73. Nykjaer A, Willnow TE (2012). Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci 35: 261-270.
74. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS et al. (2004). Sortilin is essential for proNGF-induced neuronal cell death. Nature 427: 843-848.
75. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM et al. (2006). Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 98: 1072-1080.
76. Pang DS, Robledo CJ, Carr DR, Gent TC, Vyssotski AL, Caley A et al. (2009). An unexpected role for TASK-3 potassium channels in network oscillations with implications for sleep mechanisms and anesthetic action. Proc Natl Acad Sci U S A 106: 17546-17551.
77. Patel AJ, Honore E, Maingret F, Lesage F, Fink M, Duprat F et al. (1998). A mammalian two pore domain mechano-gated S-like K+ channel. EMBO J 17: 4283-4290.
78. Patel AJ, Honore E, Lesage F, Fink M, Romey G, Lazdunski M (1999). Inhalational anesthetics activate two-pore-domain background K+ channels. Nat Neurosci 2: 422-426.
79. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
80. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M et al. (2008). Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(∗)D study. Neuropsychopharmacology 33: 2810-2819.
81. Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Rasmussen HH et al. (1997). Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem 272: 3599-3605.
82. Porsolt RD (2000). Animal models of depression: utility for transgenic research. Rev Neurosci 11: 53-58.
83. Porsolt RD, Le Pichon M, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
84. Rajan S, Preisig-Muller R, Wischmeyer E, Nehring R, Hanley PJ, Renigunta V et al. (2002). Interaction with 14-3-3 proteins promotes functional expression of the potassium channels TASK-1 and TASK-3. J Physiol 545: 13-26.
85. Sandoz G, Thummler S, Duprat F, Feliciangeli S, Vinh J, Escoubas P et al. (2006). AKAP150, a switch to convert mechano-, pH- and arachidonic acid-sensitive TREK K(+) channels into open leak channels. EMBO J 25: 5864-5872.
86. Sandoz G, Tardy MP, Thummler S, Feliciangeli S, Lazdunski M, Lesage F (2008). Mtap2 is a constituent of the protein network that regulates twik-related K+ channel expression and trafficking. J Neurosci 28: 8545-8552.
87. Sandoz G, Bell SC, Isacoff EY (2011). Optical probing of a dynamic membrane interaction that regulates the TREK1 channel. Proc Natl Acad Sci U S A 108: 2605-2610.
88. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809.
89. Sirois JE, Lei Q, Talley EM, Lynch C 3rd, Bayliss DA (2000). The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics. J Neurosci 20: 6347-6354.
90. Steiger A, Kimura M (2010). Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 44: 242-252.
91. Sundberg M, Savola S, Hienola A, Korhonen L, Lindholm D (2006). Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1. J Neurosci 26: 5402-5410.
92. Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P (2013). p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci 14: 673-680.
93. Tadic A, Wagner S, Gorbulev S, Dahmen N, Hiemke C, Braus DF et al. (2011). Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with major depressive disorder. BMC Psychiatry 11: 16.
94. Talley EM, Solorzano G, Lei Q, Kim D, Bayliss DA (2001). Cns distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 21: 7491-7505.
95. Tang B, Li Y, Nagaraj C, Morty RE, Gabor S, Stacher E et al. (2009). Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 41: 476-483.
96. Veale EL, Buswell R, Clarke CE, Mathie A (2007). Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide. Br J Pharmacol 152: 778-786.
97. Veyssiere J, Moha ou Maati H, Mazella J, Gaudriault G, Heurteaux C, Borsotto M (2014). Retroinverso analogs of spadin display increased antidepressant effects. Psychopharmacology (Berl) doi: 10.1007/s00213-014-3683-2.
98. Washburn CP, Sirois JE, Talley EM, Guyenet PG, Bayliss DA (2002). Serotonergic raphe neurons express TASK channel transcripts and a TASK-like pH- and halothane-sensitive K+ conductance. J Neurosci 22: 1256-1265.
99. Wilson CM, Naves T, Vincent F, Melloni B, Bonnaud F, Lalloue F et al. (2014). Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors. J Cell Sci 127 (Pt 18): 3983-3997.
100. Wong ML, Licinio J (2001). Research and treatment approaches to depression. Nat Rev Neurosci 2: 343-351.
101. Xi G, Zhang X, Zhang L, Sui Y, Hui J, Liu S et al. (2011). Fluoxetine attenuates the inhibitory effect of glucocorticoid hormones on neurogenesis in vitro via a two-pore domain potassium channel, TREK-1. Psychopharmacology (Berl) 214: 747-759.
102. Yang M, Lim Y, Li X, Zhong JH, Zhou XF (2011). Precursor of brain-derived neurotrophic factor (proBDNF) forms a complex with Huntingtin-associated protein-1 (HAP1) and sortilin that modulates proBDNF trafficking, degradation, and processing. J Biol Chem 286: 16272-16284.
103. Zhong P, Wang W, Pan B, Liu X, Zhang Z, Long JZ et al. (2014). Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39: 1763-1776.